About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Unicycive Therapeutics, Inc.

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Therapeutics to Participate in the H.C. Wainwright 2nd Annual Kidney Conference
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Therapeutics Announces Publication of Positive Comparison of Oxylanthanum Carbonate to Commercially Available Phosphate Binders in the American Journal of Nephrology
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th to Thursday, June 22nd at 9:00 A.M. ET
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Acceptance of Multiple Datasets to Be Presented at the European Renal Association Congress
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces up to $130 Million Financing to Commercialize and Launch Investigational New Drug Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive to Highlight Potential of UNI-494 to Restore Mitochondrial Function and Reduce Oxidative Stress at Two Upcoming Medical and Scientific Meetings
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Exclusive License and Development Agreement with Lotus for Renazorb in the Republic of Korea
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Acceptance of Three Abstracts for Presentation at the National Kidney Foundation’s Spring Clinical Meetings
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Acceptance of Four Abstracts for Presentation at the World Congress of Nephrology 2023
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive to Participate in Upcoming Investor Conferences
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Announces Third Quarter Financial Results and Provides Business Update
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
From Unicycive Therapeutics, Inc.
Via GlobeNewswire
Tickers UNCY
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.